ISOTECHNIKA AND ATRIUM ANNOUNCE LICENSING AGREEMENT FOR USE OF TAFA93 AND ISA247 WITH MEDICAL DEVICES

Isotechnika Inc. ("Isotechnika") and Atrium Medical Corporation ("Atrium") jointly announced today the signing of an exclusive worldwide licensing agreement for the use of TAFA93 and ISA247 specifically with drug eluting devices for the non-systemic treatment of vascular, cardiovascular disorders, target vessel and tissue disorders.

Canada NewsWire (http://www.newswire.ca/en/releases/archive/September2005/30/c5871.html)